Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology
Authors' conclusion
Weekly adalimumab administrations were safe and effective in controlling both articular and ocular inflammation.
Study context
- Population
- Children with psoriatic arthritis or non-infectious uveitis (idiopathic or juvenile idiopathic arthritis (JIA)-associated) who did not respond or ceased to respond to biweekly adalimumab3 females, 1 male
- Participants
- 4 children
- Exposure
- Weekly vs biweekly subcutaneous adalimumab
- Outcome
- Disease control
Methodological detailscase series
- Case series
Main finding
As reported in the abstract
In high-clearance patients only weekly administration gave predicted concentration above the therapeutic cut-off (mg/L)
9.6
Observational data: associations, not effects.
Safety
- None of the patients presented adverse events
- 0
Original publication
Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology. Arthritis Res Ther. Published 30 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →